Development and validation of LC–MS/MS with in-source collision-induced dissociation for the quantification of pegcantratinib in human skin tumors

AIM: Pegcantratinib is a mini-PEGylated K252a derivative, under clinical evaluation as an anticancer agent acting through inhibition of the tropomyosin receptor kinase. A method for quantifying pegcantratinib in skin tumor biopsies of patients was required to determine tumor drug penetration. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Zangarini, Monique, Rajan, Neil, Danilenko, Marina, Berry, Philip, Traversa, Silvio, Veal, Gareth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292016/
https://www.ncbi.nlm.nih.gov/pubmed/28111963
http://dx.doi.org/10.4155/bio-2016-0199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5292016/
https://www.ncbi.nlm.nih.gov/pubmed/28111963
http://dx.doi.org/10.4155/bio-2016-0199

Ejemplares similares